Strict guidelines and regulations have been set up by regulatory bodies such as the U.S. Food and Drug Administration (FDA) to ensure the quality, strength, and safety of pharmaceutical products. These regulations are largely codified in Title 21, Chapter I of the Code of Federal Regulations and administered by the FDA under the Department of Health and Human Services. The pharmaceutical industry helps maintain public health and well-being.
This Regulation is a Current Good Manufacturing Practice (cGMP) for Finished Pharmaceuticals. The requirements contained in subpart G relating to packaging and labeling control with a strong emphasis on expiration dating are the keystone elements of this regulation. The point of this expiration date is that it guarantees that the medication is still potent, and safe to take up to a specified duration after its expiration, and meets certain standards for potency etc., However these guidelines are in regard to quality , purity and manufacturer’s identity.
This guide was launched to help on various provisions discussed under Title 21, Chapter I, Subpart G for the drug manufacturers which includes some of the essential issues relating to compliance as well with expiration dating and packaging control. Compliance with these regulations allows manufacturers to maintain product quality, keep patients safe and be compliant.
What is Expiration Dating?
21 CFR Part 211.137 requires expiration dating within the drug product labeling. The expiration date is a key feature that certifies the potency, efficacy, and safety of a drug and ensures it meets the relevant standards of identity, strength, quality, and purity under which it was presold. Manufacturers are expected to conduct stability testing, as outlined in 211.166 for determining an expiration date.
How it is Stored and Labeled?
To provide healthcare professionals and patients with accurate and reliable expiry information, the strength of this relationship between storage conditions stated on drug product labels and expiration dating is now stipulated. Manufacturers are required to perform stability studies, as per 211.166 to demonstrate the relationship between storage condition and expiry date. Thus, the stability testing is conducted to assure that drugs remain safe and efficacious throughout their shelf life as well as patient use.
For compounds that must be reconstituted prior to dispensing, the labeling should reflect the expiration of both the unreconstituted drug product and of the reconstituted drug product. This prerequisite unveils the stability and sterility of the reconstituted product so that health practitioners may decide whether to administer or not, being right informed about it.
Exemptions and Considerations
Certain Drug Products The regulation includes written exemptions and considerations. Section 211.137(e) exempts homeopathic drug, Allergenic extracts labeled “No U.S. Standard of Potency,” as defined in § 211.137(f).
The expiration dating requirement does not apply to: (1) Drug products for investigational use referred to in 211.137(a)(6) and (g); If reconstitution is required, however, this expiration information should state the date after which the drug product in reconstituted form must not be used.
In addition, the rule recognizes a proposed exemption for human over the counter (OTC) drug products that was published in the Federal Register of September 29, 1978. However, the provisions of § 211.137(h) are not enforced for these OTC drug products if their labeling does not bear dosage limitations and sufficient stability data to support a minimum expiration date of at least three years is available.
Common Compliance Issues
Even though Title 21, Chapter I lays the foundation, there can always be compliance issues with expiration dating and packaging control. Biggest challenges pharmaceutical manufacturers face are:
Wrong expiry dating: Not setting a proper expiration date by not conducting the stability testing, leading to expired or ineffective drugs reaching the market and endangering patient health.
Poor labeling: A lack of inconsistent information on drug product labels, especially for reconstituted products, makes it unclear for healthcare professionals and can impact patient care.
Lack of information related to storage conditions compared with expiration dates, meaning you could have your distribution site storing or sending out drugs improperly which allows for the drug to become degraded and lose some of its effectiveness.
Lack of stability data: If the drug product has not stability testing to support the shelf life claimed, it will be non-compliant with the regulations, and this may affect patient safety.
Pharmaceutical manufacturers are required to comply with Title 21, Chapter I to maintain finished pharmaceutical quality, potency and safety. Following the requirements with relation to Expiry dating and packaging control are necessary so that one can fulfill the respective standards, protect the integrity of drug product as well keep the patient wellbeing. This is why stability testing is essential for storage conditions and proper labeling of drug products and helps to establish the safety and effectiveness of a drug in maintaining its cGMP status so that you make better profits in the broader market. Compliance with these standards will build trust in pharmaceutical companies, and ultimately, better patient outcomes.
Reach out to BioBoston Consulting for more information on how we could help your organization.
